BAO PHARMA-B (02659) Company Profile - Company Info, Industry & Management

返回 Overview News Financials Shareholders Profile IPO ›

Industry

Innovative Drugs & Biologics 0.02%

124 stocks in this industry

3 >7%

3 5~7%

10 3~5%

36 0~3%

15 0%

38 0~3%

13 3~5%

1 5~7%

5 >7%

Down 52 Up 57

Industry RankingsValue (HKD)Rank

Revenue (Last FY)57.64M97/112

Net Profit (Last FY)-463.56M108/125

ROE (Last FY)-24.83%85/117

Change is the 2026-10-09 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition

刘彦君 Executive Director

王征 Executive Director

李翠 Executive Director

孙玉华 Executive Director

林佳陵 Non-Executive Director

刁隽桓 Non-Executive Director

Li Chen Non-Executive Director

蔡仲曦 Independent Non-Executive Director

曾凡一 Independent Non-Executive Director

鞠佃文 Independent Non-Executive Director

张森泉 Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2026-05-26.

About this page

This page shows BAO PHARMA-B (02659) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.

BAO PHARMA-B 02659

Company Information

Industry

Management

BAO PHARMA-B 02659·

Company Information

Industry

Management

BAO PHARMA-B 02659